According to our recent payer coverage analysis for kidney cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access for kidney cancer treatments shows that under the pharmacy benefit, about 52% of the lives under commercial formularies are covered with utilization management restrictions.
Trends: In March 2021, the FDA approved Aveo Oncology’s Fotivda (tivozanib) for the treatment of adults with relapsed or refractory advanced renal cell carcinoma who have received at least two prior systemic therapies.